Contra-indicated in patients with a known hypersensitivity to morphine analogs such as codeine; in patients with respiratory depression, except in monitored settings and in the presence of resuscitative equipment; in patients with acute or severe bronchial asthma or hypercarbia; in any patient who has or is suspected of having paralytic ileus; and in patients with moderate or severe hepatic impairment.
- TRADE NAME: Opana (Endo)
- INDICATIONS: Pain (moderate to severe)
- CLASS: Analgesic, Opiate agonist
- HALF-LIFE: 7–9 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Anticholinergics, Buprenorphine, Butorphanol, Cimetidine, CNS depressants, MAO inhibitors, Nalbuphine, Pentazocine
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of oxymorphone in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
